Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China.Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China. Electronic address: yuanshuanghu@sina.com.Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, ChinaDepartment of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.Department of Oncology, Zibo Forth People's Hospital, Zibo, Shandong, China.Affiliations
刊名
Clinical oncology (Royal College of Radiologists (Great Britain))
Aims: The adverse events during antiangiogenic therapy inevitably influence a patient's quality of life. Therefore, biomarkers to identify patients who will experience adverse events would be very valuable in treatment planning. Materials and methods: Between September 2016 and December 2019, patients scheduled for single-agent apatinib were prospectively enrolled and underwent 18 F-RGD positron emission tomography/computed tomography pre-treatment. Maximum and mean standard uptake values wer...更多
Aims: The adverse events during antiangiogenic therapy inevitably influence a patient's quality of life. Therefore, biomarkers to identify patients who will experience adverse events would be very valuable in treatment planning. Materials and methods: Between September 2016 and December 2019, patients scheduled for single-agent apatinib were prospectively enrolled and underwent 18 F-RGD positron emission tomography/computed tomography pre-treatment. Maximum and mean standard uptake values were obtained from thyroid, liver, gastric cardia, gastric body, gastric pylorus and spleen. Statistical methods included the independent sample t-test, Mann-Whitney U-test, receiver operating characteristic curve analysis and chi-squared test. Results: In total, 60 patients were initially screened and consented for 18 F-RGD PET/CT scans. The three most frequent adverse events were fatigue , hypertension and nausea , accounting for 72% in the 50 patients included in the analysis. SUV max and SUV mean of thyroid and liver were significantly associated with fatigue, whereas SUV max and SUV mean of thyroid and spleen were significantly associated with hypertension and SUV max and SUV mean of thyroid and gastric cardia were significantly associated with nausea . The most significant predictors of adverse events were 18 F-RGD SUV max-liver for fatigue , SUV max-spleen for hypertension and SUV max-gastric cardia for nausea . Classified by the cut-off values for SUV max-liver , SUV max-spleen and SUV max-gastric cardia , patients with low RGD SUV max in liver, spleen and gastric cardia had statistically higher incidence of fatigue , hypertension and nausea . Conclusions: Low pre-treatment 18 F-RGD uptake in the liver, spleen and gastric cardia were predictive of the adverse events fatigue, hypertension and nausea during apatinib treatment, respectively.收起
